Bexatamig Biosimilar Bispecific Antibody (CD123 × NKp46) for Research

Cat No.: GMP-Bios-INN-1103

Anti-IL3RA/CD123 therapeutic antibody (Pre-made Bexatamig biosimilar,Bispecific (H-gamma1-VH-G1CH1h_L-kappa)_L-kappa-G1hCH2CH3) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bexatamig (development code NKp46-1) is a bispecific antibody targeting IL-3 receptor alpha (IL3RA) and NKp46 (NCR1). It is developed by Innate Pharma for acute myeloid leukaemia, myelodysplastic syndromes, precursor B-cell lymphoblastic leukaemia-lymphoma. It is in Phase I/II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1103-1mg 1mg
GMP-Bios-INN-1103-10mg 10mg
GMP-Bios-INN-1103-100mg 100mg
GMP-Bios-INN-1103-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Bexatamig biosimilar, Bispecific (H-gamma1-VH-G1CH1h_L-kappa)_L-kappa-G1hCH2CH3, Anti-IL3RA/CD123;NCR1/NKP46/NKp46/LY94/CD335 Antibody: Anti-CD123/IL3RA/Interleukin-3 receptor subunit alpha/IL-3 receptor subunit alpha therapeutic antibody
INN Name Bexatamig
Target IL3RA/CD123;NCR1/NKP46/NKp46/LY94/CD335
Format Bispecific (H-gamma1-VH-G1CH1h_L-kappa)_L-kappa-G1hCH2CH3
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-I/II
Est. Status Active
100% SI Structure 4jzj:HL:AB;6ias:HL/6iap:HL
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended 2024
Companies Innate Pharma
Conditions Approved na
Conditions Active Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma
Conditions Discontinued na
Production na
Development Tech na